Email: ir@altimmune.com
Search
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
November 11, 2024 - … and MASH. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow … Chief Executive Officer Phone: 240-654-1450 ir@altimmune.com Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Julia Weilman Burns McClellan Phone: 646-732-4443 …
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
November 7, 2024 - … and MASH. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow … Chief Executive Officer Phone: 240-654-1450 ir@altimmune.com Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Julia Weilman Burns McClellan Phone: 646-732-4443 …
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
September 30, 2024 - … and MASH. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow … Chief Executive Officer Phone: 240-654-1450 ir@altimmune.com Media Contact: Danielle Cantey Inizio Evoke, Biotech Phone: 619-826-4657 Danielle.cantey@inizioevoke.com Investor Contacts: Lee Roth Burns McClellan Phone: …
CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
September 10, 2024 - … and MASH. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow … Chief Executive Officer Phone: 240-654-1450 ir@altimmune.com Media Contact: Danielle Cantey Inizio Evoke, Biotech Phone: 619-826-4657 Danielle.cantey@inizioevoke.com Investor Contact: Lee Roth Burns McClellan Phone: …
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update
August 8, 2024 - … Investor Relations website at https://ir.altimmune.com/investors . Dial-in: To participate or dial-in, … (IR) page of the Company’s website at www.altimmune.com . The Company has used, and intends to continue to use, … and MASH. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow …
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
July 25, 2024 - … MASH. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow … Chief Executive Officer Phone: 240-654-1450 ir@altimmune.com Investor Contacts: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Julia Weilman Burns McClellan Phone: 646-732-4443 …
Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
June 23, 2024 - … MASH. For more information, please visit www.altimmune.com . Forward-Looking Statement Any statements made in this … Chief Financial Officer Phone: 240-654-1450 ir@altimmune.com Investor Contacts: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Julia Weilman Burns McClellan Phone: 646-732-4443 …
Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions
June 22, 2024 - … MASH. For more information, please visit www.altimmune.com . Forward-Looking Statement Any statements made in this … Chief Financial Officer Phone: 240-654-1450 ir@altimmune.com Investor Contacts: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Julia Weilman Burns McClellan Phone: 646-732-4443 …
Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update
May 9, 2024 - … Investor Relations website at https://ir.altimmune.com/investors . Dial-in: To participate or dial-in, register … (IR) page of the Company’s website at www.altimmune.com . The Company has used, and intends to continue to use, … and MASH. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow …
